化疗与去分化软骨肉瘤总生存改善相关吗?SEER数据库分析
基于SEER 1973-2016数据库纳入185例接受手术的去分化软骨肉瘤患者,采用Kaplan-Meier和Cox模型分析围手术期化疗与总生存的关系。校正年龄、性别、肿瘤大小、分期、分级、部位和放疗后,化疗与总生存改善无显著关联(HR 0.75,95%CI 0.49-1.12,p=0.16)。
要点
- 去分化软骨肉瘤围手术期化疗未显示总生存获益。
- 化疗组HR 0.75(95%CI 0.49-1.12,p=0.16),无统计学意义。
- 建议化疗仅在仔细考虑后使用,理想情况在临床试验中进行。
核心结论
- 去分化软骨肉瘤患者接受化疗与总生存改善无显著关联(HR 0.75,95%CI 0.49-1.12,p=0.16)。
研究设计与样本
- 回顾性队列研究,查询SEER 1973-2016数据库,纳入2000年后诊断并接受手术的185例去分化软骨肉瘤患者。
- 排除诊断时远处转移、原发部位非骨或关节、未接受癌症导向手术的患者。
- 采用Kaplan-Meier分析和Cox比例风险模型评估临床、人口学和治疗特征与总生存的关联。
主要发现
- 校正年龄、性别、肿瘤大小、分期、分级、部位和放疗状态后,化疗与总生存无显著获益(HR 0.75,95%CI 0.49-1.12,p=0.16)。
临床怎么用
- 去分化软骨肉瘤围手术期化疗缺乏明确获益证据,应仅在仔细考虑后使用,理想情况在临床试验背景下进行。
局限性
- SEER数据库化疗信息粒度有限,存在化疗错分担忧。
- 去分化软骨肉瘤样本量小,限制了检测差异的统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dedifferentiated chondrosarcoma is a chondrosarcoma subtype associated with high rates of recurrence and a poor prognosis. Others have proposed treatment of dedifferentiated chondrosarcoma using osteosarcoma protocols, including perioperative chemotherapy. However, the rarity of this condition poses difficulties in undertaking single- institution studies of sufficient sample size. QUESTION/PURPOSE: Is perioperative chemotherapy associated with improved overall survival in patients with dedifferentiated chondrosarcoma? METHODS: We queried the Surveillance, Epidemiology, and End Results (SEER) 1973 to 2016 database for patients with a diagnosis of dedifferentiated chondrosarcoma (n = 308). As dedifferentiated chondrosarcoma was only classified as a distinct entity in SEER starting in 2000, only patients treated in 2000 and later were included. We excluded from our analyses those patients with distant disease at diagnosis, a primary site of disease other than bone or joints, and those who did not receive cancer-directed surgery. These criteria yielded 185 dedifferentiated chondrosarcoma patients for inclusion. We used Kaplan-Meier analyses and Cox proportional hazards models to assess the association of clinical, demographic, and treatment characteristics on overall survival (OS). RESULTS: After controlling for confounding variables, including age, sex, tumor size, stage, grade, location, and radiation treatment status, and after adjusting for missing data, no overall survival benefit was associated with receipt of chemotherapy in patients with dedifferentiated chondrosarcoma (hazard ratio 0.75 [95% confidence interval 0.49 to 1.12]; p = 0.16). CONCLUSION: Chemotherapy treatment of dedifferentiated chondrosarcoma was not associated with improved OS. These results must be viewed cautiously, given the limited granularity of information on chemotherapy treatment, the concerns regarding chemotherapy misclassification in SEER data, and the small sample of patients with dedifferentiated chondrosarcoma, all of which limit the power to detect a difference. Our findings are nevertheless consistent with those of prior reports in which no benefit of chemotherapy could be detected. Lack of clear benefit from perioperative chemotherapy in dedifferentiated chondrosarcoma argues that it should be used only after careful consideration, and ideally in the context of a clinical trial. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Cranmer LD, Chau B, Mantilla JG, et al. Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis. Clin Orthop Relat Res. 2022. PMID: 34648466. doi:10.1097/CORR.0000000000002011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。